Stay updated on Milademetan Safety in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.

Latest updates to the Milademetan Safety in AML/MDS Clinical Trial page
- CheckyesterdayChange DetectedA site-wide notice about a lapse in government funding and an update from version v3.4.0 to v3.4.1 was added to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check8 days agoChange DetectedThe page adds a 'Show glossary' option and makes minor label/capitalization updates, along with a revision indicator (v3.4.0) replacing the prior version (v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check44 days agoChange DetectedAdded a dedicated Locations section listing California, Kansas, New York, and Texas sites; removed the separate California/Kansas/New York/Texas location entries and the HHS Vulnerability Disclosure link; updated the page revision to v3.3.3.SummaryDifference0.5%

- Check65 days agoChange DetectedThe page shows a new revision label: v3.3.2 replacing v3.3.1, a minor technical update that does not affect the study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check72 days agoChange DetectedThe page now displays an updated revision banner: Revision v3.3.1 replaces Revision v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Milademetan Safety in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.